BioXcel Therapeutics (NASDAQ:BTAI) says it has not seen any COVID-19-related changes in enrollment rates in its Phase 3 SERENITY I & II
clinical trials evaluating BXCL501 for the treatment of agitation in
schizophrenia patients. Topline data should be available mid-year.
BXCL501 is a sublingual thin film formulation of a
sedative called dexmedetomidine, the active ingredient in Pfizer’s
Precedex, approved in the U.S. in 1999 as a short-term sedative and
analgesic in critically ill or injured patients on mechanical
ventilation in an ICU setting.
https://seekingalpha.com/news/3553293-bioxcel-on-track-to-complete-bxcl501-studies-on-time
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.